Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-18

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

NCT05967949

PTCL

RECRUITING

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

NCT07139353

Peripheral T Cells Lymphoma (PTCL)

NOT_YET_RECRUITING PHASE1/PHASE2

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

NCT06122389

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

RECRUITING PHASE3

A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).

NCT06550336

Peripheral T Cell Lymphoma

ACTIVE_NOT_RECRUITING PHASE2

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

NCT04512534

Peripheral T-cell Lymphoma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL. To determine eligibility, subjects must have PTCL confirmed with a sample or specimen evaluated by the investigator.A treatment cycle is defined as 4 weeks. All eligible subjects will be treated with chidamide until disease progression, intolerable toxicity effects, death, or withdrawal of consent.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed or Refractory Peripheral T-cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chidamide

Chidamide tablets orally, twice a week.

Group Type EXPERIMENTAL

Chidamide

Intervention Type DRUG

Subjects will receive a single dose of 30 mg chidamide. Twice a week.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chidamide

Subjects will receive a single dose of 30 mg chidamide. Twice a week.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tucidinostat HBI-8000

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histopathological diagnosis, made by the investigator, of the following PTCL subtypes as defined by the WHO classification (2016) may be included: PTCL, not otherwise specified (PTCL-NOS), anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL), ALK-negative (ALK-) ALCL, angioimmunoblastic T-cell lymphoma (AITL), extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL), etc., except cutaneous form or leukemic form.
2. Patients for whom at least one measurable lesion according to Cheson Criteria 2014 at baseline.
3. Relapsed or refractory disease (including DOR shorter than 30 days) to ≥1 prior systemic therapy including, but not limited to, chemotherapy, target therapy, immunotherapy, and autologous stem cell transplantation.
4. Male or female, aged 20-75 years (inclusive).
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
6. With a life expectancy of ≥12 weeks.
7. Have not received radiotherapy, chemotherapy, immunotherapy (except for antibody therapy), or target therapy within 4 weeks prior to the start of study drug.
8. Have not received any antibody therapy within 12 weeks prior to the start of study drug.
9. Willing to provide written informed consent.

Exclusion Criteria

1. Females who are pregnant or breastfeeding, or females of childbearing potential who are not willing to use adequate contraception.
2. Patients in whom central nervous system lymphoma is recognized during screening (if suspected clinically, imaging study should be performed to confirm).
3. Have been treated with histone deacetylase (HDAC) inhibitor.
4. With a history of clinically significant QTc prolongation (\>450 ms for males or \>470 ms for females), ventricular tachycardia (VT), atrial fibrillation (AF), heart block (HB), myocardial infarction (MI) onset within one year, congestive heart failure (CHF), or any other symptomatic coronary artery disease requiring treatment.
5. The size of fluid area detected by cardiac ultrasonography in cavum pericardium is ≥10 mm during diastolic period.
6. With a history of organ transplantation.
7. With a history of allogeneic stem cell transplantation.
8. Have received autologous stem cell transplantation within 12 weeks prior to the start of study drug.
9. Have participated in a clinical trial involving investigational antibody therapy within 12 weeks prior to the start of study drug or non-antibody therapy within 4 weeks prior to the start of study drug.
10. Have received symptomatic treatment for early myelotoxicity within 7 days prior to the start of study drug.
11. With active bleeding or newly diagnosed thromboembolic disease, or with hemorrhagic tendency who are using anticoagulants.
12. With active infection of hepatitis B or C, or persistent fever within 14 days prior to the start of study drug.
13. With history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome.
14. Had a major organ surgery within 6 weeks prior to the start of study drug.
15. With abnormal hepatic function (serum total bilirubin \>1.5 x upper limit of normal \[ULN\]; alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\] \>2.5 x ULN or \>5 x ULN if liver metastases are present), abnormal renal function (serum creatinine \>1.5 x ULN), or abnormal complete blood count (absolute neutrophil counts \<1500/μL; platelet counts \<90 x 1000/μL, hemoglobin \<9 g/dL).
16. Has known psychiatric disorders or substance abuse disorders that may interfere with the patient's participation in the study or evaluation of the study results.
17. Considered by the investigator as being not suitable to participate the study.

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No